Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 87

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 87
---
 Complete survival
was observed at doses ≥11 mg/kg, with a clear dose-dependent protection from mortality and clinical symptoms.

| Figure 5. Dose response                                                                                                                
 to Nano-Mupirocin in a murine necrotizing fasciitis model.                                                                             
 Figure 6: Mortality                                                                                                                    
 during the study and disease parameters (rough hair and wound development) 48 h after the bacterial challenge. (A) A study to compare  
 one prophylactic dose of Nano-Mupirocin (50 mg/kg) vs. free mupirocin administered prophylactically and 3 and 24 h after the bacterial 
 challenge. (B) A prophylactic dose response study. (C) Nano-Mupirocin administration after the bacterial challenge vs. free mupirocin  
 administration. Survival of mice in response to increasing doses of Nano-Mupirocin.                                                    |

<div align='center'>53</div>

Figure 7. Appearance of a typical Nano-Mupirocin-treated mouse (A) vs. an untreated one (B) 24 h after bacterial challenge.

Figure 8: Plasma profile of mupirocin after IV administration of 40 mg/kg free vs. Nano-Mupirocin.

Reference: Ahuva Cern, Ayelet Michael-Gayego, Yaelle Bavli, Erez Korena, Amiram Goldblum, Allon E. Moses, Yan Q. Xiong and Yechezkel Barenholz* Nano-Mupirocin: enabling the parenteral activity of mupirocin DOI 10.1515/ejnm-2016-0006

<div align='center'>54</div>

| 5. | Biodistribution      
 and Pharmacokinetics |

PK studies in mice (n=4 per time point) showed
that Nano-Mupirocin had a terminal half-life of 262 minutes vs. 5.3 minutes for free mupirocin. The area under the curve (AUC) was ~97-fold
higher for Nano-Mupirocin, confirming sustained systemic exposure. Biodistribution studies showed accumulation in infected organs and
in mucosal secretions (e.g., vaginal fluid), maintaining drug concentrations well above the MIC₉₀ for >24h

Figure 9: Vaginal Smear Fluorescence. Fluorescence microscopy of vaginal smears. (A,B) are overlays of Differential interference contrast (DIC) and Fluorescent